Patent application number | Description | Published |
20110144090 | COMPOUNDS AND METHODS OF USE THEREOF - Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds. | 06-16-2011 |
20130053341 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit. | 02-28-2013 |
20140315886 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds (I) that modulate stri-atal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I). | 10-23-2014 |
20150284365 | COMPOUNDS AND METHODS OF USE THEREOF - Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds. | 10-08-2015 |
20150307477 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. | 10-29-2015 |
Patent application number | Description | Published |
20120283238 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 11-08-2012 |
20130123231 | ACC INHIBITORS AND USES THEREOF - The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same. | 05-16-2013 |
20130231328 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 09-05-2013 |
20140018357 | IRAK INHIBITORS AND USES THEREOF - The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same. | 01-16-2014 |
20140018361 | IRAK INHIBITORS AND USES THEREOF - The present invention provides furano- and pyrrolo-pyrimidine and pyridine compounds, compositions thereof, and methods of using the same. | 01-16-2014 |
20140194417 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 07-10-2014 |
20150025093 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 01-22-2015 |
20150094305 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 04-02-2015 |
20150203510 | ACC INHIBITORS AND USES THEREOF - The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same. | 07-23-2015 |
20150266875 | TYK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. | 09-24-2015 |
20150329498 | IRAK INHIBITORS AND USES THEREOF - The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of IRAK enzymes. | 11-19-2015 |
20160002256 | IRAK INHIBITORS AND USES THEREOF - The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same. | 01-07-2016 |
Patent application number | Description | Published |
20090054495 | CCR9 inhibitors and methods of use thereof - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 02-26-2009 |
20100093802 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 04-15-2010 |
20100280074 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 11-04-2010 |
20100324093 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 12-23-2010 |
20110313000 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 12-22-2011 |
20140107160 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 04-17-2014 |
Patent application number | Description | Published |
20090325300 | APPARATUS AND METHOD FOR DETECTION OF TRACE CHEMICALS - A method of rapidly detecting trace materials including biohazards, toxins, radioactive materials, and narcotics in situ is disclosed. A corresponding apparatus is disclosed. A trace of the material is collected on a pad of the card component, collected by swiping the pad on suspected surface or exposure to the suspected air volume. A novel card component is disclosed that when inserted in a chemical detection unit (CDU), releases reaction chemicals from flexible walled capsules in desired sequence. The exposed pad containing trace material and chemicals are heated in the chemical detection unit to produce a spectral pattern that is analyzed by the optical electronics in the CDU and results are displayed, stored and/or transmitted over a communications network. | 12-31-2009 |
20140314625 | APPARATUS AND METHOD FOR DETECTION OF TRACE CHEMICALS - A method of rapidly detecting trace materials including biohazards, toxins, radioactive materials, and narcotics in situ is disclosed. A corresponding apparatus is disclosed. A trace of the material is collected on a pad of the card component, collected by swiping the pad on suspected surface or exposure to the suspected air volume. A novel card component is disclosed that when inserted in a chemical detection unit (CDU), releases reaction chemicals from flexible walled capsules in desired sequence. The exposed pad containing trace material and chemicals are heated in the chemical detection unit to produce a spectral pattern that is analyzed by the optical electronics in the CDU and results are displayed, stored and/or transmitted over a communications network. | 10-23-2014 |
Patent application number | Description | Published |
20100313757 | AIR COOLING SYSTEM INCORPORATING MEMBRANE-FREE FILTER AND/OR INTEGRAL FRAMING FOR FILTER - A filter for an electronics cooling unit of a telecommunications base station, the electronics cooling unit adapted to receive fresh air into a housing of the cooling unit through an opening communicating with the external environment. The filter includes a structural support configured to be mounted to said housing, a gasket sealingly engaging the structural support and adapted to engage the housing; and a filter media supported by the structural support, the filter media being free of a membrane type layer and including a fiber entanglement selected to prevent ingress of water sufficient to pass a salt fog test consistent with GR-487-CORE and in accordance with ASTM B 117. | 12-16-2010 |
20100313760 | MEMBRANE-FREE FILTER AND/OR INTEGRAL FRAMING FOR FILTER - A filter for an electronics cooling unit of a telecommunications base station, the electronics cooling unit adapted to receive fresh air into a housing of the cooling unit through an opening communicating with the external environment. The filter includes a structural support configured to be mounted to said housing, a gasket sealingly engaging the structural support and adapted to engage the housing; and a filter media supported by the structural support, the filter media being free of a membrane type layer and including a fiber entanglement selected to prevent ingress of water sufficient to pass a salt fog test consistent with GR-487-CORE and in accordance with ASTM B 117. | 12-16-2010 |
20130269531 | Membrane-Free Filter and/or Integral Framing for Filter - A filter for an electronics cooling unit of a telecommunications base station, the electronics cooling unit adapted to receive fresh air into a housing of the cooling unit through an opening communicating with the external environment. The filter includes a structural support configured to be mounted to said housing, a gasket sealingly engaging the structural support and adapted to engage the housing; and a filter media supported by the structural support, the filter media being free of a membrane type layer and including a fiber entanglement selected to prevent ingress of water sufficient to pass a salt fog test consistent with GR-487-CORE and in accordance with ASTM B 117. | 10-17-2013 |
Patent application number | Description | Published |
20130283485 | PLANT GROWING SYSTEM CONTAINING A SUPER AMOUNT OF A CONTROLLED-RELEASED FERTILIZER AND METHODS OF USING THE SAME - The invention relates to a plant growing system having (a) plant life; (b) a super amount of a controlled-release fertilizer to provide season-long performance; and (c) growing media. The planting growing system may also include a moisture control agent or a plant protection agent. Despite the high EC values of the growing system, the combination of materials that make up the growing system nevertheless produces superior performing plants with darker green, healthier-looking leaves; superior growth, fill and spread; more abundant production of flowers and fruits; and a more developed, sustaining root system. Moreover, these plants are far less susceptible to the effects of pests such as fungi (e.g., | 10-24-2013 |
20150020233 | PLANTS COMPRISING EVENTS PP009-401, PP009-415, AND PP009-469, COMPOSITIONS, SEQUENCES, AND METHODS FOR DETECTION THEREOF - The invention provides glyphosate tolerant transgenic turfgrass plants, plant material, and seeds that have a specific transformation event. Also provided are assays for detecting the presence of the event. The invention also provides sequences for a variant EPSPS gene and a GAO2X gene, cassettes, and plants comprising the variant EPSPS gene and a GAO2X gene. | 01-15-2015 |
20150047072 | PLANT GROWING SYSTEM CONTAINING A SUPER AMOUNT OF A CONTROLLED-RELLEASED FERTILIZER AND METHODS OF USING THE SAME - The invention relates to a plant growing system having (a) plant life; (b) a super amount of a controlled-release fertilizer to provide season-long performance; and (c) growing media. The planting growing system may also include a moisture control agent or a plant protection agent. Despite the high EC values of the growing system, the combination of materials that make up the growing system nevertheless produces superior performing plants with darker green, healthier-looking leaves; superior growth, fill and spread; more abundant production of flowers and fruits; and a more developed, sustaining root system. Moreover, these plants are far less susceptible to the effects of pests such as fungi (e.g., | 02-12-2015 |
Patent application number | Description | Published |
20100092955 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME - A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed. | 04-15-2010 |
20110055938 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS - A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region. | 03-03-2011 |
20120058903 | Gel Microdrop Composition and Method of Using the Same - A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed. | 03-08-2012 |
20140068796 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS - A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region. | 03-06-2014 |
20140082759 | Transgenic Chicken Comprising an Inactivated Immunoglobulin Gene - A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immuno -well as globulin gene is provided, as we cells and targeting vectors for making the same. | 03-20-2014 |
20150322168 | In Vivo Method for Generating Diversity in a Protein Scaffold - A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain. | 11-12-2015 |